Teva Pharmaceutical Indus... (TEVA)
Teva Pharmaceutical Industries Statistics
Share Statistics
Teva Pharmaceutical Industries has 1.15B shares outstanding. The number of shares has increased by 1.21% in one year.
Shares Outstanding | 1.15B |
Shares Change (YoY) | 1.21% |
Shares Change (QoQ) | 0.14% |
Owned by Institutions (%) | 58.65% |
Shares Floating | 1.15B |
Failed to Deliver (FTD) Shares | 16.24K |
FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 15.8M, so 1.39% of the outstanding shares have been sold short.
Short Interest | 15.8M |
Short % of Shares Out | 1.39% |
Short % of Float | 1.39% |
Short Ratio (days to cover) | 1.26 |
Valuation Ratios
The PE ratio is -15.43 and the forward PE ratio is 6.55. Teva Pharmaceutical Industries's PEG ratio is -0.08.
PE Ratio | -15.43 |
Forward PE | 6.55 |
PS Ratio | 1.53 |
Forward PS | 1.1 |
PB Ratio | 4.71 |
P/FCF Ratio | 33.76 |
PEG Ratio | -0.08 |
Enterprise Valuation
Teva Pharmaceutical Industries Limited has an Enterprise Value (EV) of 28.61B.
EV / Earnings | -17.46 |
EV / Sales | 1.73 |
EV / EBITDA | -94.42 |
EV / EBIT | -94.42 |
EV / FCF | 38.2 |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 3.36.
Current Ratio | 0.98 |
Quick Ratio | 0.75 |
Debt / Equity | 3.36 |
Total Debt / Capitalization | 77.09 |
Cash Flow / Debt | 0.07 |
Interest Coverage | -0.3 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on capital (ROIC) is -1.63%.
Return on Equity (ROE) | -0.31% |
Return on Assets (ROA) | -0.04% |
Return on Capital (ROIC) | -1.63% |
Revenue Per Employee | $488,138.79 |
Profits Per Employee | $-48,359.49 |
Employee Count | 33,892 |
Asset Turnover | 0.42 |
Inventory Turnover | 2.82 |
Taxes
Income Tax | 355M |
Effective Tax Rate | -0.53 |
Stock Price Statistics
The stock price has increased by 8.66% in the last 52 weeks. The beta is 0.83, so Teva Pharmaceutical Industries's price volatility has been higher than the market average.
Beta | 0.83 |
52-Week Price Change | 8.66% |
50-Day Moving Average | 17.56 |
200-Day Moving Average | 17.81 |
Relative Strength Index (RSI) | 39.79 |
Average Volume (20 Days) | 12.26M |
Income Statement
In the last 12 months, Teva Pharmaceutical Industries had revenue of 16.54B and earned -1.64B in profits. Earnings per share was -1.45.
Revenue | 16.54B |
Gross Profit | 8.06B |
Operating Income | -303M |
Net Income | -1.64B |
EBITDA | -303M |
EBIT | -303M |
Earnings Per Share (EPS) | -1.45 |
Balance Sheet
The company has 3.3B in cash and 18.08B in debt, giving a net cash position of -14.78B.
Cash & Cash Equivalents | 3.3B |
Total Debt | 18.08B |
Net Cash | -14.78B |
Retained Earnings | -15.17B |
Total Assets | 39.33B |
Working Capital | -244M |
Cash Flow
In the last 12 months, operating cash flow was 1.25B and capital expenditures -498M, giving a free cash flow of 749M.
Operating Cash Flow | 1.25B |
Capital Expenditures | -498M |
Free Cash Flow | 749M |
FCF Per Share | 0.66 |
Margins
Gross margin is 48.74%, with operating and profit margins of -1.83% and -9.91%.
Gross Margin | 48.74% |
Operating Margin | -1.83% |
Pretax Margin | -7.76% |
Profit Margin | -9.91% |
EBITDA Margin | -1.83% |
EBIT Margin | -1.83% |
FCF Margin | 4.53% |
Dividends & Yields
TEVA pays an annual dividend of $1.19, which amounts to a dividend yield of 5.8%.
Dividend Per Share | $1.19 |
Dividend Yield | 5.8% |
Dividend Growth (YoY) | 0% |
Payout Ratio | -82.07% |
Earnings Yield | -9.25% |
FCF Yield | 4.17% |
Analyst Forecast
The average price target for TEVA is $24.5, which is 56.2% higher than the current price. The consensus rating is "Buy".
Price Target | $24.5 |
Price Target Difference | 56.2% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Stock Splits
The last stock split was on Jul 1, 2004. It was a forward split with a ratio of 2:1.
Last Split Date | Jul 1, 2004 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | 0.71 |
Piotroski F-Score | 4 |